MBX Biosciences, Inc. Statistics
Want to see MBX full AI Analyst Report?
MBX Biosciences, Inc. (MBX) Stock Statistics & Valuation Metrics
Total Valuation
MBX Biosciences, Inc. has a market cap or net worth of $2.80B. The enterprise value is $2.37B.
- Market Cap
- $2.80B
- Enterprise Value
- $2.37B
Share Statistics
MBX Biosciences, Inc. has 49,656,265 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 49,656,265
- Owned by Insiders
- 25.68%
- Owned by Institutions
- 34.63%
Financial Efficiency
MBX Biosciences, Inc.’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -26.51%.
- Return on Equity (ROE)
- -0.24
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -26.51%
- Return on Capital Employed (ROCE)
- -0.27
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.38M
- Employee Count
- 63
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of MBX Biosciences, Inc. is -18.86. MBX Biosciences, Inc.’s PEG ratio is 0.65.
- PE Ratio
- -18.86
- PS Ratio
- 0.00
- PB Ratio
- 5.93
- Price to FCF
- -28.85
- Price to Operating Cash Flow
- -29.19
- PEG Ratio
- 0.65
Income Statement
In the last 12 months, MBX Biosciences, Inc. had revenue of 0 and earned -86.97M in profits. Earnings per share was -2.38.
- Revenue
- 0
- Gross Profit
- -248.00K
- Operating Income
- -98.06M
- Pretax Income
- -86.97M
- Net Income
- -86.97M
- EBITDA
- -86.72M
- Earnings Per Share (EPS)
- -2.38
Cash Flow
In the last 12 months, operating cash flow was -96.01M and capital expenditures -3.32M, giving a free cash flow of -99.33M billion.
- Operating Cash Flow
- -96.01M
- Free Cash Flow
- -99.33M
- Free Cash Flow per Share
- -2.05
Dividends & Yields
MBX Biosciences, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.57%
- Earnings Yield
- -5.18%
Stock Price Statistics
- Beta
- 1.95
- 52-Week Price Change
- 131.71%
- 50-Day Moving Average
- 56.34
- 200-Day Moving Average
- 46.07
- Relative Strength Index (RSI)
- 54.97
- Average Volume (3m)
- 518.83K
Important Dates
MBX Biosciences, Inc. upcoming earnings date is Mar 22, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 22, 2027
- Ex-Dividend Date
- ―
Financial Position
MBX Biosciences, Inc. as a current ratio of 24.62, with Debt / Equity ratio of 0.16%
- Current Ratio
- 24.62
- Quick Ratio
- 24.62
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.86
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, MBX Biosciences, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
MBX Biosciences, Inc. EV to EBITDA ratio is -17.64, with an EV/FCF ratio of -26.39.
- EV to Sales
- 0.00
- EV to EBITDA
- -17.64
- EV to Free Cash Flow
- -26.39
- EV to Operating Cash Flow
- -27.30
Balance Sheet
MBX Biosciences, Inc. has $481.59M in cash and marketable securities with $3.29M in debt, giving a net cash position of $478.30M billion.
- Cash & Marketable Securities
- $481.59M
- Total Debt
- $3.29M
- Net Cash
- $478.30M
- Net Cash Per Share
- $9.63
- Tangible Book Value Per Share
- $9.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for MBX Biosciences, Inc. is $96.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $96.67
- Price Target Upside
- 67.48% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -27.83%
Scores
- Smart Score
- 9
- AI Score
- 52
